Mogamulizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mogamulizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CCR4
Clinical data
Trade names Poteligeo
Routes of
administration
Intravenous
ATC code
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6520H10072N1736O2020S42
Molar mass 146.44 kg/mol
 NYesY (what is this?)  (verify)

Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It was approved in Japan in 2012 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.[1]

Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd.[2] It has also been licensed to Amgen for development as a therapy for Asthma.[3]

In 2016 it was in phase 1 clinical trials in combination with utomilumab (PF-05082566) for solid cancers.[4]

References[edit]

  1. ^ Subramaniam, J; Whiteside G; McKeage K; Croxtall J (18 June 2012). "Mogamulizumab: First Global Approval". Drugs. 72 (9): 1293–1298. PMID 22686619. doi:10.2165/11631090-000000000-00000. Retrieved 10 September 2012. 
  2. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab" (PDF). American Medical Association. 
  3. ^ "Kyowa Hakko Kirin R&D Pipeline" (PDF). Kyowa Hakko Kirin. Retrieved 10 September 2012. 
  4. ^ A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors